{"id":"dexamethasone-phosphate","rwe":[{"pmid":"41411223","year":"2025","title":"Dexamethasone Dosing of Human Perilymph Compared for Common Delivery Protocols Using Inner Ear Simulations.","finding":"","journal":"Audiology & neuro-otology","studyType":"Clinical Study"},{"pmid":"41340367","year":"2026","title":"Skin-to-Muscle Deep Tissue Stimulation System for Muscle Atrophy.","finding":"","journal":"Advanced materials (Deerfield Beach, Fla.)","studyType":"Clinical Study"},{"pmid":"41090873","year":"2025","title":"Magnetic Cationic Liposomes-Based Delivery System Reduces Drug-Induced Cytotoxicity in an In Vitro Model of Hearing Loss.","finding":"","journal":"Nanomaterials (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"40699120","year":"2025","title":"Intravitreal aflibercept alone versus combination with dexamethasone phosphate for diabetic macular edema: A randomized phase-2 clinical trial.","finding":"","journal":"Arquivos brasileiros de oftalmologia","studyType":"Clinical Study"},{"pmid":"40619775","year":"2025","title":"Adopting a consensus on the dose of antenatal steroids used by obstetric and neonatal services in Singapore in anticipation of imminent preterm birth.","finding":"","journal":"Singapore medical journal","studyType":"Clinical Study"}],"_fda":{"id":"02bf3273-f0c8-448c-9f74-eb009fee9299","set_id":"0277cc0a-2fd4-4605-a310-b613be84ee26","openfda":{"unii":["AI9376Y64P"],"route":["INTRAMUSCULAR","INTRAVENOUS","INTRA-ARTICULAR","INTRALESIONAL","SOFT TISSUE"],"rxcui":["309696","1116927","1812194"],"spl_id":["02bf3273-f0c8-448c-9f74-eb009fee9299"],"brand_name":["Dexamethasone Sodium Phosphate"],"spl_set_id":["0277cc0a-2fd4-4605-a310-b613be84ee26"],"package_ndc":["0641-0367-21","0641-0367-25","0641-6145-01","0641-6145-25","0641-6146-01","0641-6146-10","0641-6146-25"],"product_ndc":["0641-0367","0641-6145","0641-6146"],"generic_name":["DEXAMETHASONE SODIUM PHOSPHATE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["DEXAMETHASONE SODIUM PHOSPHATE"],"manufacturer_name":["Hikma Pharmaceuticals USA Inc."],"application_number":["ANDA087702","ANDA084282"],"is_original_packager":[true]},"version":"21","warnings":["WARNINGS Serious Neurologic Adverse Reactions with Epidural Administration Serious neurologic events, some resulting in death, have been reported with epidural injection of corticosteroids. Specific events reported include, but are not limited to, spinal cord infarction, paraplegia, quadriplegia, cortical blindness, and stroke. These serious neurologic events have been reported with and without use of fluoroscopy. The safety and effectiveness of epidural administration of corticosteroids have not been established, and corticosteroids are not approved for this use. In patients on corticosteroid therapy subject to any unusual stress, increased dosage of rapidly acting corticosteroids before, during and after the stressful situation is indicated. Immunosuppression and Increased Risk of Infection Corticosteroids, including Dexamethasone Sodium Phosphate, suppress the immune system and increase the risk of infection with any pathogen, including viral, bacterial, fungal, protozoan, or helminthic pathogens. Corticosteroids can: Reduce resistance to new infections Exacerbate existing infections Increase the risk of disseminated infections Increase the risk of reactivation or exacerbation of latent infections Mask some signs of infection Corticosteroid-associated infections can be mild but can be severe and at times fatal. The rate of infectious complications increases with increasing corticosteroid dosages. Monitor for the development of infection and consider Dexamethasone Sodium Phosphate withdrawal or dosage reduction as needed. Tuberculosis If Dexamethasone Sodium Phosphate is used to treat a condition in patients with latent tuberculosis or tuberculin reactivity, tuberculosis may occur. Closely monitor such patients for reactivation. During prolonged therapy, patients with latent tuberculosis or tuberculin reactivity should receive chemoprophylaxis. Varicella Zoster and Measles Viral Infections Varicella and measles can have a serious or even fatal course in non-immune patients taking corticosteroids, including Dexamethasone Sodium Phosphate. In corticosteroid-treated patients who have not had these diseases or are non- immune, particular care should be taken to avoid exposure to varicella and measles: If a Dexamethasone Sodium Phosphate -treated patient is exposed to varicella, prophylaxis with varicella zoster immune globulin may be indicated. If varicella develops, treatment with antiviral agents may be considered. If a Dexamethasone Sodium Phosphate -treated patient is exposed to measles, prophylaxis with immunoglobulin may be indicated. Hepatitis B Virus Reactivation Hepatitis B virus reactivation can occur in patients who are hepatitis B carriers treated with immunosuppressive dosages of corticosteroids, including Dexamethasone Sodium Phosphate. Reactivation can also occur infrequently in corticosteroid-treated patients who appear to have resolved hepatitis B infection. Screen patients for hepatitis B infection before initiating immunosuppressive (e.g., prolonged) treatment with Dexamethasone Sodium Phosphate. For patients who show evidence of hepatitis B infection, recommend consultation with physicians with expertise in managing hepatitis B regarding monitoring and consideration for hepatitis B antiviral therapy. Fungal Infections Corticosteroids, including Dexamethasone Sodium Phosphate, may exacerbate systemic fungal infections; therefore, avoid Dexamethasone Sodium Phosphate use in the presence of such infections unless Dexamethasone Sodium Phosphate is needed to control drug reactions. For patients on chronic Dexamethasone Sodium Phosphate therapy who develop systemic fungal infections, Dexamethasone Sodium Phosphate withdrawal or dosage reduction is recommended. Amebiasis Corticosteroids, including Dexamethasone Sodium Phosphate, may activate latent amebiasis. Therefore, it is recommended that latent amebiasis or active amebiasis be ruled out before initiating Dexamethasone Sodium Phosphate in patients who have spent time in the tropics or patients with unexplained diarrhea. Strongyloides Infestation Corticosteroids, including Dexamethasone Sodium Phosphate, should be used with great care in patients with known or suspected Strongyloides (threadworm) infestation. In such patients, corticosteroid-induced immunosuppression may lead to Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia. Cerebral Malaria Avoid corticosteroids, including Dexamethasone Sodium Phosphate, in patients with cerebral malaria. Kaposi’s Sarcoma Kaposi’s sarcoma has been reported to occur in patients receiving corticosteroid therapy, most often for chronic conditions. Discontinuation of corticosteroids may result in clinical improvement of Kaposi’s sarcoma. Prolonged use of corticosteroids may produce posterior subcapsular cataracts, glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections due to fungi or viruses. Usage in Pregnancy Since adequate human reproduction studies have not been done with corticosteroids, use of these drugs in pregnancy, nursing mothers or women of childbearing potential requires that the possible benefits of the drug be weighed against the potential hazards to the mother and embryo or fetus. Infants born of mothers who have received substantial doses of corticosteroids during pregnancy should be carefully observed for signs of hypoadrenalism. Average and large doses of cortisone or hydrocortisone can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium. These effects are less likely to occur with the synthetic derivatives except when used in large doses. Patients with a stressed myocardium should be observed carefully and the drug administered slowly since premature ventricular contractions may occur with rapid administration. Dietary salt restriction and potassium supplementation may be necessary. All corticosteroids increase calcium excretion. While on corticosteroid therapy patients should not be vaccinated against smallpox. Other immunization procedures should not be undertaken in patients who are on corticosteroids, especially in high doses, because of possible hazards of neurological complications and lack of antibody response. The use of Dexamethasone Sodium Phosphate Injection in active tuberculosis should be restricted to those cases of fulminating or disseminated tuberculosis in which the corticosteroid is used for the management of the disease in conjunction with an appropriate anti-tuberculosis regimen. If corticosteroids are indicated in patients with latent tuberculosis or tuberculin reactivity, close observation is necessary as reactivation of the disease may occur. During prolonged corticosteroid therapy, these patients should receive chemoprophylaxis. Because rare instances of anaphylactoid reactions have occurred in patients receiving parenteral corticosteroid therapy, appropriate precautionary measures should be taken prior to administration, especially when the patient has a history of allergy to any drug. Dexamethasone Sodium Phosphate Injection contains sodium sulfite, a sulfite that may cause allergic type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people."],"pregnancy":["Usage in Pregnancy Since adequate human reproduction studies have not been done with corticosteroids, use of these drugs in pregnancy, nursing mothers or women of childbearing potential requires that the possible benefits of the drug be weighed against the potential hazards to the mother and embryo or fetus. Infants born of mothers who have received substantial doses of corticosteroids during pregnancy should be carefully observed for signs of hypoadrenalism. Average and large doses of cortisone or hydrocortisone can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium. These effects are less likely to occur with the synthetic derivatives except when used in large doses. Patients with a stressed myocardium should be observed carefully and the drug administered slowly since premature ventricular contractions may occur with rapid administration. Dietary salt restriction and potassium supplementation may be necessary. All corticosteroids increase calcium excretion. While on corticosteroid therapy patients should not be vaccinated against smallpox. Other immunization procedures should not be undertaken in patients who are on corticosteroids, especially in high doses, because of possible hazards of neurological complications and lack of antibody response. The use of Dexamethasone Sodium Phosphate Injection in active tuberculosis should be restricted to those cases of fulminating or disseminated tuberculosis in which the corticosteroid is used for the management of the disease in conjunction with an appropriate anti-tuberculosis regimen. If corticosteroids are indicated in patients with latent tuberculosis or tuberculin reactivity, close observation is necessary as reactivation of the disease may occur. During prolonged corticosteroid therapy, these patients should receive chemoprophylaxis. Because rare instances of anaphylactoid reactions have occurred in patients receiving parenteral corticosteroid therapy, appropriate precautionary measures should be taken prior to administration, especially when the patient has a history of allergy to any drug. Dexamethasone Sodium Phosphate Injection contains sodium sulfite, a sulfite that may cause allergic type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people."],"description":["DESCRIPTION Dexamethasone sodium phosphate injection, USP is a water-soluble inorganic ester of dexamethasone which produces a rapid response even when injected intramuscularly. Dexamethasone sodium phosphate, a synthetic adrenocortical steroid, is a white or slightly yellow crystalline powder. It is freely soluble in water and is exceedingly hygroscopic. The molecular weight is 516.41. It is designated chemically as 9-fluoro-11β,17-dihydroxy-16α-methyl-21-(phosphonooxy)pregna-1,4-diene-3, 20-dione disodium salt. The molecular formula is: C 22 H 28 FNa 2 O 8 P and the structural formula is: Dexamethasone Sodium Phosphate Injection is a sterile solution of dexamethasone sodium phosphate for intravenous and intramuscular use. The 4 mg/mL strength may also be used for intra-articular, intralesional and soft tissue administration. Each mL of Dexamethasone Sodium Phosphate Injection 4 mg/mL contains dexamethasone sodium phosphate, equivalent to 4 mg dexamethasone phosphate or 3.33 mg dexamethasone. Inactive ingredients per mL: 1 mg sodium sulfite anhydrous, 19.4 mg sodium citrate anhydrous and 10.42 mg (0.01 mL) benzyl alcohol (preservative) in Water for Injection. Each mL of Dexamethasone Sodium Phosphate Injection 10 mg/mL contains dexamethasone sodium phosphate, equivalent to 10 mg dexamethasone phosphate or 8.33 mg dexamethasone. Inactive ingredients per mL: 1.5 mg sodium sulfite anhydrous, 16.5 mg sodium citrate anhydrous and 10.42 mg (0.01 mL) benzyl alcohol (preservative) in Water for Injection. The pH of both concentrations is 7.0-8.5; sodium hydroxide and/or citric acid used, if needed, for pH adjustment. Sealed under nitrogen. Structural formula"],"precautions":["PRECAUTIONS Drug-induced secondary adrenocortical insufficiency may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted. Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently. There is an enhanced effect of corticosteroids in patients with hypothyroidism and in those with cirrhosis. Corticosteroids should be used cautiously in patients with ocular herpes simplex for fear of corneal perforation. The lowest possible dose of corticosteroid should be used to control the condition under treatment, and when reduction in dosage is possible, the reduction must be gradual. Psychic derangements may appear when corticosteroids are used ranging from euphoria, insomnia, mood swings, personality changes, and severe depression to frank psychotic manifestations. Also, existing emotional instability or psychotic tendencies may be aggravated by corticosteroids. Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia. Steroids should be used with caution in nonspecific ulcerative colitis, if there is a probability of impending perforation, abscess, or other pyogenic infection, also in diverticulitis, fresh intestinal anastomoses, active or latent peptic ulcer, renal insufficiency, hypertension, osteoporosis, and myasthenia gravis. Growth and development of infants and children on prolonged corticosteroid therapy should be carefully followed. Patients who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to chickenpox or measles and, if exposed, to obtain medical advice. Intra-articular injection of a corticosteroid may produce systemic as well as local effects. Appropriate examination of any joint fluid present is necessary to exclude a septic process. A marked increase in pain accompanied by local swelling, further restriction of joint motion, fever, and malaise are suggestive of septic arthritis. If this complication occurs and the diagnosis of sepsis is confirmed, appropriate antimicrobial therapy should be instituted. Local injection of a steroid into a previously infected joint is to be avoided. Corticosteroids should not be injected into unstable joints. Although controlled clinical trials have shown corticosteroids to be effective in speeding the resolution of acute exacerbations of multiple sclerosis they do not show that they affect the ultimate outcome or natural history of the disease. The studies do show that relatively high doses of corticosteroids are necessary to demonstrate a significant effect. (See Dosage and Administration Section ). Since complications of treatment with glucocorticoids are dependent on the size of the dose and the duration of treatment a risk/benefit decision must be made in each individual case as to dose and duration of treatment and as to whether daily or intermittent therapy should be used."],"how_supplied":["HOW SUPPLIED Dexamethasone Sodium Phosphate Injection, USP is available in the following package: 4 mg/mL 1 mL vials packaged in 25s (NDC 0641-6145-25) 5 mL vials packaged in 10s (NDC 0641-6146-10) 10 mg/mL 1 mL vials packaged in 25s (NDC 0641-0367-25) Storage Protect from light: Keep covered in carton until time of use. Store at 20° to 25°C (68° to 77°F), excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Avoid freezing. Do not use if solution is hazy or has a precipitate. Do not autoclave. To report SUSPECTED ADVERSE REACTIONS, contact Hikma Pharmaceuticals USA Inc. at 1-877-845-0689, or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. For Product Inquiry call 1-877-845-0689. Manufactured by: Hikma Pharmaceuticals USA Inc. Berkeley Heights, NJ 07922 USA Revised December 2024 462-331-09"],"effective_time":"20260122","adverse_reactions":["ADVERSE REACTIONS Fluid and electrolyte disturbances: Sodium retention Fluid retention Congestive heart failure in susceptible patients Potassium loss Hypokalemic alkalosis Hypertension Musculoskeletal: Muscle weakness Steroid myopathy Loss of muscle mass Osteoporosis Vertebral compression fractures Aseptic necrosis of femoral and humeral heads Pathologic fracture of long bones Gastrointestinal: Peptic ulcer with possible subsequent perforation and hemorrhage Pancreatitis Abdominal distention Ulcerative esophagitis Dermatological: Impaired wound healing Thin fragile skin Facial erythema Increased sweating May suppress reactions to skin tests Petechiae and ecchymoses Neurological: Convulsions Increased intracranial pressure with papilledema (pseudotumor cerebri) usually after treatment Vertigo Headache Ophthalmic: Posterior subcapsular cataracts Increased intraocular pressure Glaucoma Endocrine: Menstrual irregularities Development of cushingoid state Suppression of growth in children Secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery, or illness Decreased carbohydrate tolerance Manifestations of latent diabetes mellitus Increased requirements for insulin or oral hypoglycemic agents in diabetics Metabolic: Negative nitrogen balance due to protein catabolism Miscellaneous: Hyperpigmentation or hypopigmentation Subcutaneous and cutaneous atrophy Sterile abscess Postinjection flare following intra-articular use Charcot-like arthropathy Itching, burning, tingling in the ano-genital region"],"contraindications":["CONTRAINDICATIONS Systemic fungal infections."],"storage_and_handling":["Storage Protect from light: Keep covered in carton until time of use. Store at 20° to 25°C (68° to 77°F), excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Avoid freezing. Do not use if solution is hazy or has a precipitate. Do not autoclave. To report SUSPECTED ADVERSE REACTIONS, contact Hikma Pharmaceuticals USA Inc. at 1-877-845-0689, or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. For Product Inquiry call 1-877-845-0689. Manufactured by: Hikma Pharmaceuticals USA Inc. Berkeley Heights, NJ 07922 USA Revised December 2024 462-331-09"],"clinical_pharmacology":["ACTIONS Naturally occurring glucocorticoids (hydrocortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their potent anti-inflammatory effects in disorders of many organ systems. Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body’s immune responses to diverse stimuli."],"indications_and_usage":["INDICATIONS A. Intravenous or intramuscular administration. When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: 1. Endocrine disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic diseases Pemphigus Severe erythema multiforme (Stevens-Johnson Syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic states Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) 6. Ophthalmic diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Allergic corneal marginal ulcers Keratitis 7. Gastrointestinal diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory diseases Symptomatic Sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate anti-tuberculosis chemotherapy Loeffler's syndrome not manageable by other means Aspiration pneumonitis 9. Hematologic disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (I.V. only; I.M. administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous states To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 12. Nervous system Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate anti-tuberculosis chemotherapy Trichinosis with neurologic or myocardial involvement Diagnostic testing of adrenocortical hyperfunction Cerebral edema of diverse etiologies in conjunction with adequate neurological evaluation and management. B. Intra-articular or soft tissue administration. When the strength and dosage form of the drug lend the preparation to the treatment of the condition, those products labeled for intra-articular or soft tissue administration are indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Synovitis of osteoarthritis Rheumatoid arthritis Acute and subacute bursitis Acute gouty arthritis Epicondylitis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis C. Intralesional administration. When the strength and dosage form of the drug lend the preparation to the treatment of the condition, those products labeled for intralesional administration are indicated for: Keloids Localized hypertrophic, infiltrated, inflammatory lesions of: lichen planus, psoriatic plaques, granuloma annulare, and lichen simplex chronicus (neurodermatitis) Discoid lupus erythematosus Necrobiosis lipoidica diabeticorum Alopecia areata They also may be useful in cystic tumors of an aponeurosis tendon (ganglia)."],"dosage_and_administration":["DOSAGE AND ADMINISTRATION A. Intravenous or intramuscular administration. The initial dosage of Dexamethasone Sodium Phosphate Injection may vary from 0.50 mg/day to 9.0 mg/day depending on the specific disease entity being treated. In situations of less severity, lower doses will generally suffice while in selected patients higher initial doses may be required. Usually the parenteral dosage ranges are one-third to one-half the oral dose given every 12 hours. However, in certain overwhelming, acute, life-threatening situations, administration of dosages exceeding the usual dosages may be justified and may be in multiples of the oral dosages. For the treatment of unresponsive shock high pharmacologic doses of this product are currently recommended. Reported regimens range from 1 to 6 mg/kg of body weight as a single intravenous injection to 40 mg initially followed by repeat intravenous injection every 2 to 6 hours while shock persists. For the treatment of cerebral edema in adults an initial intravenous dose of 10 mg is recommended followed by 4 mg intramuscularly every six hours until maximum response has been noted. This regimen may be continued for several days postoperatively in patients requiring brain surgery. Oral dexamethasone, 1 to 3 mg t.i.d., should be given as soon as possible and dosage tapered off over a period of five to seven days. Nonoperative cases may require continuous therapy to remain free of symptoms of increased intracranial pressure. The smallest effective dose should be used in children, preferably orally. This may approximate 0.2 mg/kg/24 hours in divided doses. In treatment of acute exacerbations of multiple sclerosis daily doses of 200 mg of prednisolone for a week followed by 80 mg every other day or 4–8 mg dexamethasone every other day for 1 month have been shown to be effective. The initial dosage should be maintained or adjusted until a satisfactory response is noted. If after a reasonable period of time there is a lack of satisfactory clinical response, Dexamethasone Sodium Phosphate Injection should be discontinued and the patient transferred to other appropriate therapy. It should be emphasized that dosage requirements are variable and must be individualized on the basis of the disease under treatment and the response of the patient. After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached. It should be kept in mind that constant monitoring is needed in regard to drug dosage. Included in the situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient’s individual drug responsiveness and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment. In this latter situation it may be necessary to increase the dosage of dexamethasone sodium phosphate injection, USP for a period of time consistent with the patient’s condition. If after a long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly. B. Intra-articular, soft tissue or intralesional administration. The dose for instrasynovial administration is usually 2 to 4 mg for large joints and 0.8 to 1 mg for small joints. For soft tissue and bursal injections a dose of 2 to 4 mg is recommended. Ganglia require a dose of 1 to 2 mg. A dose of 0.4 to 1 mg is used for injection into tendon sheaths. Injection into intervertebral joints should not be attempted at any time and hip joint injection cannot be recommended as an office procedure. Intrasynovial and soft tissue injections should be employed only when affected areas are limited to 1 or 2 sites. It should be remembered that corticoids provide palliation only and that other conventional or curative methods of therapy should be employed when indicated. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Frequency of injection usually ranges from once every 3 to 5 days to once every 2 to 3 weeks. Frequent intra-articular injection may cause damage to joint tissue."],"spl_product_data_elements":["Dexamethasone Sodium Phosphate Dexamethasone Sodium Phosphate DEXAMETHASONE SODIUM PHOSPHATE DEXAMETHASONE DEXAMETHASONE PHOSPHATE SODIUM SULFITE SODIUM CITRATE BENZYL ALCOHOL WATER SODIUM HYDROXIDE CITRIC ACID MONOHYDRATE Dexamethasone Sodium Phosphate Dexamethasone Sodium Phosphate DEXAMETHASONE SODIUM PHOSPHATE DEXAMETHASONE DEXAMETHASONE PHOSPHATE SODIUM SULFITE SODIUM CITRATE BENZYL ALCOHOL WATER SODIUM HYDROXIDE CITRIC ACID MONOHYDRATE Dexamethasone Sodium Phosphate Dexamethasone Sodium Phosphate DEXAMETHASONE SODIUM PHOSPHATE DEXAMETHASONE DEXAMETHASONE PHOSPHATE SODIUM SULFITE SODIUM CITRATE BENZYL ALCOHOL WATER SODIUM HYDROXIDE CITRIC ACID MONOHYDRATE"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL NDC 0641- 0367 -21 Rx only Dexamethasone Sodium Phosphate Injection, USP 10 mg/mL (dexamethasone phosphate equivalent) For IV or IM use ONLY Protect from light 1 mL Vial NDC 0641- 0367 -25 Rx only Dexamethasone Sodium Phosphate Injection, USP 10 mg/mL (dexamethasone phosphate equivalent) For Intravenous or Intramuscular use ONLY 25 x 1 mL Vials 10 mg-mL vial 10 mg-mL 25 x 1 shelfpack","PRINCIPAL DISPLAY PANEL NDC 0641- 6145 -01 Rx only Dexamethasone Sodium Phosphate Injection, USP 4 mg/mL (dexamethasone phosphate equivalent) For IV, IM, Intralesional, Intra-articular or Soft Tissue use Protect from light 1 mL Vial NDC 0641- 6145 -25 Rx only Dexamethasone Sodium Phosphate Injection, USP 4 mg/mL (dexamethasone phosphate equivalent) For Intravenous, Intramuscular, Intralesional, Intra-articular or Soft Tissue use 25 x 1 mL Vials unit label carton label","PRINCIPAL DISPLAY PANEL NDC 0641- 6146 -01 Rx only Dexamethasone Sodium Phosphate Injection, USP 20 mg per 5 mL (4 mg/mL) (dexamethasone phosphate equivalent) For IV, IM, Intralesional, Intra-articular or Soft Tissue use 5 mL Vial NDC 0641- 6146 -10 Rx only Dexamethasone Sodium Phosphate Injection, USP 20 mg per 5 mL (4 mg/mL) (dexamethasone phosphate equivalent) For Intravenous, Intramuscular, Intralesional, Intra-articular or Soft Tissue use 10 x 5 mL Vials unit label carton label"]},"tags":[{"label":"Corticosteroid","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Mineralocorticoid receptor","category":"target"},{"label":"NR3C2","category":"gene"},{"label":"NR3C1","category":"gene"},{"label":"PGR","category":"gene"},{"label":"Intralesional","category":"route"},{"label":"Intravenous","category":"route"},{"label":"Intraocular","category":"route"},{"label":"Injection","category":"form"},{"label":"Active","category":"status"},{"label":"Merck","category":"company"},{"label":"Approved 1950s","category":"decade"},{"label":"Anti-Inflammatory Agents","category":"pharmacology"},{"label":"Antiemetics","category":"pharmacology"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Antineoplastic Agents, Hormonal","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Gastrointestinal Agents","category":"pharmacology"},{"label":"Glucocorticoids","category":"pharmacology"},{"label":"Hormones","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"llr":454.831,"date":"","count":319,"signal":"Neutrophil count decreased","source":"DrugCentral FAERS","actionTaken":"Reported 319 times (LLR=455)"},{"llr":336.43,"date":"","count":402,"signal":"Febrile neutropenia","source":"DrugCentral FAERS","actionTaken":"Reported 402 times (LLR=336)"},{"llr":315.529,"date":"","count":365,"signal":"Platelet count decreased","source":"DrugCentral FAERS","actionTaken":"Reported 365 times (LLR=316)"},{"llr":271.1,"date":"","count":167,"signal":"Myelosuppression","source":"DrugCentral FAERS","actionTaken":"Reported 167 times (LLR=271)"},{"llr":240.147,"date":"","count":314,"signal":"White blood cell count decreased","source":"DrugCentral FAERS","actionTaken":"Reported 314 times (LLR=240)"},{"llr":239.649,"date":"","count":239,"signal":"Interstitial lung disease","source":"DrugCentral FAERS","actionTaken":"Reported 239 times (LLR=240)"},{"llr":209.177,"date":"","count":54,"signal":"Choroiditis","source":"DrugCentral FAERS","actionTaken":"Reported 54 times (LLR=209)"},{"llr":171.976,"date":"","count":72,"signal":"Endophthalmitis","source":"DrugCentral FAERS","actionTaken":"Reported 72 times (LLR=172)"},{"llr":155.455,"date":"","count":153,"signal":"Hepatic function abnormal","source":"DrugCentral FAERS","actionTaken":"Reported 153 times (LLR=155)"},{"llr":147.627,"date":"","count":72,"signal":"Intraocular pressure increased","source":"DrugCentral FAERS","actionTaken":"Reported 72 times (LLR=148)"},{"llr":141.829,"date":"","count":128,"signal":"Bone marrow failure","source":"DrugCentral FAERS","actionTaken":"Reported 128 times (LLR=142)"},{"llr":133.444,"date":"","count":310,"signal":"Neutropenia","source":"DrugCentral FAERS","actionTaken":"Reported 310 times (LLR=133)"},{"llr":115.642,"date":"","count":505,"signal":"Pyrexia","source":"DrugCentral FAERS","actionTaken":"Reported 505 times (LLR=116)"},{"llr":111.149,"date":"","count":322,"signal":"Decreased appetite","source":"DrugCentral FAERS","actionTaken":"Reported 322 times (LLR=111)"},{"llr":108.065,"date":"","count":92,"signal":"Disseminated intravascular coagulation","source":"DrugCentral FAERS","actionTaken":"Reported 92 times (LLR=108)"}],"commonSideEffects":[{"effect":"Congestive heart failure","drugRate":"reported","severity":"serious"},{"effect":"Osteoporosis","drugRate":"reported","severity":"serious"},{"effect":"Vertebral compression fractures","drugRate":"reported","severity":"serious"},{"effect":"Aseptic necrosis of femoral and humeral heads","drugRate":"reported","severity":"serious"},{"effect":"Pathologic fracture of long bones","drugRate":"reported","severity":"serious"},{"effect":"Peptic ulcer with possible subsequent perforation and hemorrhage","drugRate":"reported","severity":"serious"},{"effect":"Pancreatitis","drugRate":"reported","severity":"serious"},{"effect":"Ulcerative esophagitis","drugRate":"reported","severity":"serious"},{"effect":"Impaired wound healing","drugRate":"reported","severity":"serious"},{"effect":"Steroid myopathy","drugRate":"reported","severity":"serious"},{"effect":"Loss of muscle mass","drugRate":"reported","severity":"serious"},{"effect":"Hypokalemic alkalosis","drugRate":"reported","severity":"serious"},{"effect":"Hypertension","drugRate":"reported","severity":"serious"},{"effect":"Posterior subcapsular cataracts","drugRate":"reported","severity":"serious"},{"effect":"Increased intraocular pressure","drugRate":"reported","severity":"serious"},{"effect":"Glaucoma","drugRate":"reported","severity":"serious"},{"effect":"Menstrual irregularities","drugRate":"reported","severity":"serious"},{"effect":"Development of cushingoid state","drugRate":"reported","severity":"serious"},{"effect":"Suppression of growth in children","drugRate":"reported","severity":"serious"},{"effect":"Secondary adrenocortical and pituitary unresponsiveness","drugRate":"reported","severity":"serious"},{"effect":"Decreased carbohydrate tolerance","drugRate":"reported","severity":"serious"},{"effect":"Manifestations of latent diabetes mellitus","drugRate":"reported","severity":"serious"},{"effect":"Increased requirements for insulin or oral hypoglycemic agents in diabetics","drugRate":"reported","severity":"serious"},{"effect":"Muscle weakness","drugRate":"reported","severity":"mild"},{"effect":"Potassium loss","drugRate":"reported","severity":"mild"},{"effect":"Fluid retention","drugRate":"reported","severity":"mild"},{"effect":"Sodium retention","drugRate":"reported","severity":"mild"}],"contraindications":["Systemic fungal infections"],"specialPopulations":{"Pregnancy":"Since adequate human reproduction studies have not been done with corticosteroids, use of these drugs in pregnancy, nursing mothers or women of childbearing potential requires that the possible benefits of the drug be weighed against the potential hazards to the mother and embryo or fetus. Infants born of mothers who have received substantial doses of corticosteroids during pregnancy should be carefully observed for signs of hypoadrenalism.","Geriatric use":"No overall differences in safety and effectiveness have been observed between elderly and younger patients.","Paediatric use":"Safety and effectiveness in pediatric patients have not been established."}},"trials":[],"aliases":[],"company":"Merck & Co.","patents":[{"type":"Method of Use","number":"10028965","applicant":"EYEPOINT PHARMACEUTICALS INC","territory":"US","tradeName":"DEXYCU KIT","expiryDate":"2034-05-23"},{"type":"Method of Use","number":"8563027","applicant":"OCULAR THERAPEUTIX INC","territory":"US","tradeName":"DEXTENZA","expiryDate":"2030-02-12"},{"type":"Method of Use","number":"12144889","applicant":"OCULAR THERAPEUTIX INC","territory":"US","tradeName":"DEXTENZA","expiryDate":"2041-04-26"},{"type":"Method of Use","number":"12150896","applicant":"OCULAR THERAPEUTIX INC","territory":"US","tradeName":"DEXTENZA","expiryDate":"2036-10-07"},{"type":"Formulation","number":"11097061","applicant":"EYEPOINT PHARMACEUTICALS INC","territory":"US","tradeName":"DEXYCU KIT","expiryDate":"2039-06-23"},{"type":"Method of Use","number":"10022502","applicant":"EYEPOINT PHARMACEUTICALS INC","territory":"US","tradeName":"DEXYCU KIT","expiryDate":"2034-06-22"},{"type":"Method of Use","number":"11458041","applicant":"OCULAR THERAPEUTIX INC","territory":"US","tradeName":"DEXTENZA","expiryDate":"2037-11-16"},{"type":"Formulation","number":"11304961","applicant":"DEXCEL PHARMA TECHNOLOGIES LTD","territory":"US","tradeName":"HEMADY","expiryDate":"2037-12-18"},{"type":"Formulation","number":"8409606","applicant":"OCULAR THERAPEUTIX INC","territory":"US","tradeName":"DEXTENZA","expiryDate":"2030-05-14"},{"type":"Formulation","number":"10799642","applicant":"EYEPOINT PHARMACEUTICALS INC","territory":"US","tradeName":"DEXYCU KIT","expiryDate":"2032-05-11"},{"type":"Formulation","number":"10159683","applicant":"EYEPOINT PHARMACEUTICALS INC","territory":"US","tradeName":"DEXYCU KIT","expiryDate":"2034-05-23"},{"type":"Formulation","number":"10537585","applicant":"DEXCEL PHARMA TECHNOLOGIES LTD","territory":"US","tradeName":"HEMADY","expiryDate":"2037-12-18"}],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$7.2702/ML","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$2,617","description":"DEXAMETHASONE 0.1% EYE DROP","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=dexamethasone phosphate","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:06:45.034915+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T02:06:45.034851+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:06:50.201578+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=dexamethasone phosphate","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:06:50.579305+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:06:43.918793+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:10:21.503302+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:06:43.918817+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Glucocorticoid receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:06:52.042196+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2021430/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:06:51.702834+00:00"},"safety.commonSideEffects":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"ADVERSE REACTIONS Fluid and electrolyte disturbances: Sodium retention Fluid retention Congestive heart failure in susceptible patients Potassium loss Hypokalemic alkalosis Hypertension Musculoskeletal: Muscle weakness Steroid myopathy Loss of muscle mass Osteoporosis Vertebral compression fractures Aseptic necrosis of femoral and humeral heads Pathologic fracture of long bones Gastrointestinal: Peptic ulcer with possible subsequent perforation and hemorrhage Pancreatitis Abdominal distention Ul","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:06:55.803830+00:00"},"safety.contraindications":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:06:57.398731+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA087702, ANDA084282","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:06:43.918821+00:00"}},"allNames":"dexamethasone sodium phosphate","offLabel":[],"synonyms":["dexamethasone phosphate","dexamethasone sodium phosphate","decadron","dexamethasone phosphoric acid"],"timeline":[{"date":"1959-09-02","type":"positive","source":"DrugCentral","milestone":"FDA approval (Merck)"}],"approvals":[{"date":"1959-09-02","orphan":false,"company":"MERCK","regulator":"FDA"}],"brandName":"Dexamethasone Sodium Phosphate","ecosystem":[],"mechanism":{"target":"Androgen receptor, Glucocorticoid receptor, Mineralocorticoid receptor","novelty":"First-in-class","targets":[{"gene":"NR3C2","source":"DrugCentral","target":"Mineralocorticoid receptor","protein":"Mineralocorticoid receptor"},{"gene":"NR3C1","source":"DrugCentral","target":"Glucocorticoid receptor","protein":"Glucocorticoid receptor"},{"gene":"PGR","source":"DrugCentral","target":"Progesterone receptor","protein":"Progesterone receptor"},{"gene":"AR","source":"DrugCentral","target":"Androgen receptor","protein":"Androgen receptor"}],"moaClass":"Corticosteroid Hormone Receptor Agonists","modality":"Small Molecule","drugClass":"Corticosteroid","explanation":"","oneSentence":"","technicalDetail":"Dexamethasone sodium phosphate is a synthetic corticosteroid that exerts its effects by binding to the mineralocorticoid receptor, which is a type of nuclear receptor that regulates gene expression. This binding causes a decrease in the production of pro-inflammatory cytokines and an increase in the production of anti-inflammatory cytokines, leading to a reduction in inflammation and immune response."},"commercial":{"launchDate":"1959","_launchSource":"DrugCentral (FDA 1959-09-02, MERCK)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3920","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=dexamethasone%20phosphate","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=dexamethasone phosphate","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:30:24.576194","_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T02:10:21.650280+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"alclometasone dipropionate","drugSlug":"alclometasone-dipropionate","fdaApproval":"1982-12-14","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"amcinonide","drugSlug":"amcinonide","fdaApproval":"1979-10-18","genericCount":4,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"auranofin","drugSlug":"auranofin","fdaApproval":"1985-05-24","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"beclometasone dipropionate","drugSlug":"beclometasone-dipropionate","fdaApproval":"1976-05-12","relationship":"same-target"},{"drugName":"betamethasone","drugSlug":"betamethasone","fdaApproval":"1961-04-17","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"betamethasone acetate","drugSlug":"betamethasone-acetate","fdaApproval":"1965-03-03","relationship":"same-target"},{"drugName":"betamethasone benzoate","drugSlug":"betamethasone-benzoate","fdaApproval":"","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"betamethasone dipropionate","drugSlug":"betamethasone-dipropionate","fdaApproval":"1975-01-29","patentExpiry":"Aug 31, 2030","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"betamethasone phosphate","drugSlug":"betamethasone-phosphate","fdaApproval":"1965-03-03","relationship":"same-target"},{"drugName":"betamethasone valerate","drugSlug":"betamethasone-valerate","fdaApproval":"1967-09-02","genericCount":12,"patentStatus":"Off-patent — generic available","relationship":"same-target"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"},{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"dexamethasone phosphate","indications":{"approved":[{"id":"dexamethasone-phosphate-primary-or-secondary-adrenocor","name":"Primary or secondary adrenocortical insufficiency","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with primary or secondary adrenocortical insufficiency","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with primary or secondary adrenocortical insufficiency","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-acute-adrenocortical-insuffici","name":"Acute adrenocortical insufficiency","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with acute adrenocortical insufficiency","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with acute adrenocortical insufficiency","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-shock-unresponsive-to-conventi","name":"Shock unresponsive to conventional therapy","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with shock unresponsive to conventional therapy and suspected or confirmed adrenocortical insufficiency","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with shock unresponsive to conventional therapy and suspected or confirmed adrenocortical insufficiency","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-congenital-adrenal-hyperplasia","name":"Congenital adrenal hyperplasia","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with congenital adrenal hyperplasia","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with congenital adrenal hyperplasia","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-nonsuppurative-thyroiditis","name":"Nonsuppurative thyroiditis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with nonsuppurative thyroiditis","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with nonsuppurative thyroiditis","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-hypercalcemia-associated-with-","name":"Hypercalcemia associated with cancer","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with hypercalcemia associated with cancer","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with hypercalcemia associated with cancer","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-post-traumatic-osteoarthritis","name":"Post-traumatic osteoarthritis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with post-traumatic osteoarthritis","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with post-traumatic osteoarthritis","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-synovitis-of-osteoarthritis","name":"Synovitis of osteoarthritis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with synovitis of osteoarthritis","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with synovitis of osteoarthritis","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-rheumatoid-arthritis","name":"Rheumatoid arthritis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with rheumatoid arthritis, including juvenile rheumatoid arthritis","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with rheumatoid arthritis, including juvenile rheumatoid arthritis","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-acute-and-subacute-bursitis","name":"Acute and subacute bursitis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with acute and subacute bursitis","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with acute and subacute bursitis","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-epicondylitis","name":"Epicondylitis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with epicondylitis","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with epicondylitis","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-acute-nonspecific-tenosynoviti","name":"Acute nonspecific tenosynovitis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with acute nonspecific tenosynovitis","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with acute nonspecific tenosynovitis","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-acute-gouty-arthritis","name":"Acute gouty arthritis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with acute gouty arthritis","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with acute gouty arthritis","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-psoriatic-arthritis","name":"Psoriatic arthritis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with psoriatic arthritis","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with psoriatic arthritis","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-ankylosing-spondylitis","name":"Ankylosing spondylitis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with ankylosing spondylitis","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with ankylosing spondylitis","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-systemic-lupus-erythematosus","name":"Systemic lupus erythematosus","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with systemic lupus erythematosus","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with systemic lupus erythematosus","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-acute-rheumatic-carditis","name":"Acute rheumatic carditis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with acute rheumatic carditis","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with acute rheumatic carditis","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-pemphigus","name":"Pemphigus","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with pemphigus","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with pemphigus","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-severe-erythema-multiforme-(st","name":"Severe erythema multiforme (Stevens-Johnson Syndrome)","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with severe erythema multiforme (Stevens-Johnson Syndrome)","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with severe erythema multiforme (Stevens-Johnson Syndrome)","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-exfoliative-dermatitis","name":"Exfoliative dermatitis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with exfoliative dermatitis","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with exfoliative dermatitis","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-bullous-dermatitis-herpetiform","name":"Bullous dermatitis herpetiformis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with bullous dermatitis herpetiformis","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with bullous dermatitis herpetiformis","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-severe-seborrheic-dermatitis","name":"Severe seborrheic dermatitis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with severe seborrheic dermatitis","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with severe seborrheic dermatitis","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-severe-psoriasis","name":"Severe psoriasis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with severe psoriasis","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with severe psoriasis","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-mycosis-fungoides","name":"Mycosis fungoides","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with mycosis fungoides","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with mycosis fungoides","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-bronchial-asthma","name":"Bronchial asthma","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with bronchial asthma","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with bronchial asthma","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-contact-dermatitis","name":"Contact dermatitis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with contact dermatitis","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with contact dermatitis","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-atopic-dermatitis","name":"Atopic dermatitis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with atopic dermatitis","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with atopic dermatitis","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-serum-sickness","name":"Serum sickness","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with serum sickness","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with serum sickness","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-seasonal-or-perennial-allergic","name":"Seasonal or perennial allergic rhinitis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with seasonal or perennial allergic rhinitis","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with seasonal or perennial allergic rhinitis","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-drug-hypersensitivity-reaction","name":"Drug hypersensitivity reactions","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with drug hypersensitivity reactions","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with drug hypersensitivity reactions","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-urticarial-transfusion-reactio","name":"Urticarial transfusion reactions","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with urticarial transfusion reactions","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with urticarial transfusion reactions","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-acute-noninfectious-laryngeal-","name":"Acute noninfectious laryngeal edema","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with acute noninfectious laryngeal edema","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with acute noninfectious laryngeal edema","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-herpes-zoster-ophthalmicus","name":"Herpes zoster ophthalmicus","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with herpes zoster ophthalmicus","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with herpes zoster ophthalmicus","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-iritis,-iridocyclitis","name":"Iritis, iridocyclitis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with iritis, iridocyclitis","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with iritis, iridocyclitis","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-chorioretinitis","name":"Chorioretinitis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with chorioretinitis","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with chorioretinitis","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-diffuse-posterior-uveitis-and-","name":"Diffuse posterior uveitis and choroiditis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with diffuse posterior uveitis and choroiditis","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with diffuse posterior uveitis and choroiditis","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-optic-neuritis","name":"Optic neuritis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with optic neuritis","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with optic neuritis","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-sympathetic-ophthalmia","name":"Sympathetic ophthalmia","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with sympathetic ophthalmia","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with sympathetic ophthalmia","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-anterior-segment-inflammation","name":"Anterior segment inflammation","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with anterior segment inflammation","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with anterior segment inflammation","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-allergic-conjunctivitis","name":"Allergic conjunctivitis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with allergic conjunctivitis","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with allergic conjunctivitis","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-allergic-corneal-marginal-ulce","name":"Allergic corneal marginal ulcers","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with allergic corneal marginal ulcers","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with allergic corneal marginal ulcers","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-keratitis","name":"Keratitis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with keratitis","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with keratitis","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-ulcerative-colitis","name":"Ulcerative colitis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with ulcerative colitis","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with ulcerative colitis","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-regional-enteritis","name":"Regional enteritis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with regional enteritis","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with regional enteritis","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-symptomatic-sarcoidosis","name":"Symptomatic Sarcoidosis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with symptomatic sarcoidosis","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with symptomatic sarcoidosis","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-berylliosis","name":"Berylliosis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with berylliosis","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with berylliosis","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-fulminating-or-disseminated-pu","name":"Fulminating or disseminated pulmonary tuberculosis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with fulminating or disseminated pulmonary tuberculosis","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with fulminating or disseminated pulmonary tuberculosis","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-loeffler's-syndrome","name":"Loeffler's syndrome","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with Loeffler's syndrome not manageable by other means","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with Loeffler's syndrome not manageable by other means","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-aspiration-pneumonitis","name":"Aspiration pneumonitis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with aspiration pneumonitis","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with aspiration pneumonitis","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-acquired-(autoimmune)-hemolyti","name":"Acquired (autoimmune) hemolytic anemia","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with acquired (autoimmune) hemolytic anemia","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with acquired (autoimmune) hemolytic anemia","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-idiopathic-thrombocytopenic-pu","name":"Idiopathic thrombocytopenic purpura in adults","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Adults with idiopathic thrombocytopenic purpura","pivotalTrial":null,"restrictions":[],"patientPopulation":"Adults with idiopathic thrombocytopenic purpura","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-secondary-thrombocytopenia-in-","name":"Secondary thrombocytopenia in adults","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Adults with secondary thrombocytopenia","pivotalTrial":null,"restrictions":[],"patientPopulation":"Adults with secondary thrombocytopenia","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-erythroblastopenia-(rbc-anemia","name":"Erythroblastopenia (RBC anemia)","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with erythroblastopenia (RBC anemia)","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with erythroblastopenia (RBC anemia)","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-congenital-(erythroid)-hypopla","name":"Congenital (erythroid) hypoplastic anemia","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with congenital (erythroid) hypoplastic anemia","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with congenital (erythroid) hypoplastic anemia","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-leukemias-and-lymphomas-in-adu","name":"Leukemias and lymphomas in adults","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Adults with leukemias and lymphomas","pivotalTrial":null,"restrictions":[],"patientPopulation":"Adults with leukemias and lymphomas","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-acute-leukemia-of-childhood","name":"Acute leukemia of childhood","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Children with acute leukemia","pivotalTrial":null,"restrictions":[],"patientPopulation":"Children with acute leukemia","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-nephrotic-syndrome","name":"Nephrotic syndrome","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-acute-exacerbations-of-multipl","name":"Acute exacerbations of multiple sclerosis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with acute exacerbations of multiple sclerosis","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with acute exacerbations of multiple sclerosis","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-tuberculous-meningitis-with-su","name":"Tuberculous meningitis with subarachnoid block","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with tuberculous meningitis with subarachnoid block or impending block","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with tuberculous meningitis with subarachnoid block or impending block","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-trichinosis-with-neurologic-or","name":"Trichinosis with neurologic or myocardial involvement","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with trichinosis with neurologic or myocardial involvement","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with trichinosis with neurologic or myocardial involvement","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-diagnostic-testing-of-adrenoco","name":"Diagnostic testing of adrenocortical hyperfunction","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients undergoing diagnostic testing of adrenocortical hyperfunction","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients undergoing diagnostic testing of adrenocortical hyperfunction","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"},{"id":"dexamethasone-phosphate-cerebral-edema","name":"Cerebral edema","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with cerebral edema","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with cerebral edema","diagnosticRequired":null,"brandNameForIndication":"Dexamethasone Sodium Phosphate"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"alclometasone-dipropionate","brandName":"alclometasone dipropionate","genericName":"alclometasone dipropionate","approvalYear":"1982","relationship":"same-target"},{"drugId":"amcinonide","brandName":"amcinonide","genericName":"amcinonide","approvalYear":"1979","relationship":"same-target"},{"drugId":"auranofin","brandName":"auranofin","genericName":"auranofin","approvalYear":"1985","relationship":"same-target"},{"drugId":"beclometasone-dipropionate","brandName":"beclometasone dipropionate","genericName":"beclometasone dipropionate","approvalYear":"1976","relationship":"same-target"},{"drugId":"betamethasone","brandName":"betamethasone","genericName":"betamethasone","approvalYear":"1961","relationship":"same-target"},{"drugId":"betamethasone-acetate","brandName":"betamethasone acetate","genericName":"betamethasone acetate","approvalYear":"1965","relationship":"same-target"},{"drugId":"betamethasone-benzoate","brandName":"betamethasone benzoate","genericName":"betamethasone benzoate","approvalYear":"","relationship":"same-target"},{"drugId":"betamethasone-dipropionate","brandName":"betamethasone dipropionate","genericName":"betamethasone dipropionate","approvalYear":"1975","relationship":"same-target"},{"drugId":"betamethasone-phosphate","brandName":"betamethasone phosphate","genericName":"betamethasone phosphate","approvalYear":"1965","relationship":"same-target"},{"drugId":"betamethasone-valerate","brandName":"betamethasone valerate","genericName":"betamethasone valerate","approvalYear":"1967","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT06317662","phase":"PHASE2","title":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-05","conditions":["Acute Leukemia of Ambiguous Lineage","B Acute Lymphoblastic Leukemia"],"enrollment":153,"completionDate":"2028-12-31"},{"nctId":"NCT03914625","phase":"PHASE3","title":"A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-03","conditions":["B Acute Lymphoblastic Leukemia","B Lymphoblastic Lymphoma","Down Syndrome"],"enrollment":6720,"completionDate":"2027-09-30"},{"nctId":"NCT03798678","phase":"PHASE1","title":"CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-08","conditions":["Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":36,"completionDate":"2026-06-30"},{"nctId":"NCT06169215","phase":"PHASE2","title":"Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-23","conditions":["Multiple Myeloma"],"enrollment":70,"completionDate":"2026-09-30"},{"nctId":"NCT07463807","phase":"PHASE1,PHASE2","title":"Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-06-26","conditions":["Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":162,"completionDate":"2026-08-31"},{"nctId":"NCT00792948","phase":"PHASE2","title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-01","conditions":["Acute Lymphoblastic Leukemia","Adult B Acute Lymphoblastic Leukemia","Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","Adult L1 Acute Lymphoblastic Leukemia","Adult L2 Acute Lymphoblastic Leukemia","Adult T Acute Lymphoblastic Leukemia","Recurrent Adult Acute Lymphoblastic Leukemia"],"enrollment":97,"completionDate":"2027-01-06"},{"nctId":"NCT06948084","phase":"PHASE2","title":"Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-29","conditions":["Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":80,"completionDate":"2028-02-28"},{"nctId":"NCT04530565","phase":"PHASE3","title":"Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-25","conditions":["B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1"],"enrollment":348,"completionDate":"2028-07-01"},{"nctId":"NCT04847453","phase":"PHASE1","title":"Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-08-03","conditions":["Recurrent AL Amyloidosis","Refractory AL Amyloidosis"],"enrollment":24,"completionDate":"2026-06-30"},{"nctId":"NCT07444710","phase":"PHASE1","title":"Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-20","conditions":["Ann Arbor Stage II Mantle Cell Lymphoma","Ann Arbor Stage III Mantle Cell Lymphoma","Ann Arbor Stage IV Mantle Cell Lymphoma"],"enrollment":16,"completionDate":"2027-09-01"},{"nctId":"NCT00644228","phase":"PHASE3","title":"Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-07-28","conditions":["DS Stage I Multiple Myeloma","DS Stage II Multiple Myeloma","DS Stage III Multiple Myeloma"],"enrollment":525,"completionDate":"2026-09-18"},{"nctId":"NCT02491632","phase":"PHASE2,PHASE3","title":"Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-08-13","conditions":["Advanced Malignant Neoplasm","Fatigue","Metastatic Malignant Neoplasm","Recurrent Malignant Neoplasm","Refractory Malignant Neoplasm"],"enrollment":90,"completionDate":"2026-12-31"},{"nctId":"NCT03418038","phase":"PHASE2","title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-03-23","conditions":["Clonal Cytopenia of Undetermined Significance","High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","Recurrent Diffuse Large B-Cell Lymphoma","Recurrent Hodgkin Lymphoma","Recurrent Lymphoma","Refractory Diffuse Large B-Cell Lymphoma","Refractory Lymphoma","Chronic Myelomonocytic Leukemia"],"enrollment":80,"completionDate":"2033-11-02"},{"nctId":"NCT06918431","phase":"PHASE2","title":"Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2025-10-10","conditions":["B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative","Lymphoblastic Lymphoma"],"enrollment":53,"completionDate":"2029-03-30"},{"nctId":"NCT04883242","phase":"PHASE2","title":"Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2021-07-29","conditions":["Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":30,"completionDate":"2031-12-31"},{"nctId":"NCT05292664","phase":"PHASE1","title":"Venetoclax Basket Trial for High Risk Hematologic Malignancies","status":"RECRUITING","sponsor":"Andrew E. Place, MD","startDate":"2023-03-29","conditions":["Myelodysplastic Syndromes, de Novo","Myelodysplastic Syndromes, Secondary","Myelodysplastic Syndromes, Previously Treated","Treatment-Related Acute Myeloid Leukemia","Therapy-Related Myelodysplastic Syndrome","Acute Lymphoblastic Leukemia, in Relapse","Acute Lymphoblastic Leukemia With Failed Remission","Lymphoblastic Lymphoma, in Relapse","Lymphoblastic Lymphoma, Refractory","Acute Leukemia of Ambiguous Lineage in Relapse","Acute Leukemia of Ambiguous Lineage"],"enrollment":30,"completionDate":"2030-07-02"},{"nctId":"NCT03959085","phase":"PHASE3","title":"Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2019-10-31","conditions":["B Acute Lymphoblastic Leukemia","B Lymphoblastic Lymphoma","Central Nervous System Leukemia","Mixed Phenotype Acute Leukemia","Testicular Leukemia"],"enrollment":5951,"completionDate":"2032-03-31"},{"nctId":"NCT06203912","phase":"PHASE1","title":"Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Elvira Umyarova","startDate":"2024-03-05","conditions":["Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":3,"completionDate":"2026-08-31"},{"nctId":"NCT06930690","phase":"PHASE1,PHASE2","title":"Dexamethasone for Ureteral STent Symptoms (DUSTS)","status":"NOT_YET_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2026-04","conditions":["Ureteral Stent-Related Symptom"],"enrollment":70,"completionDate":"2027-04"},{"nctId":"NCT05023369","phase":"PHASE4","title":"This is a Study to Verify if Periarticular Hip Injection of Corticosteroid After Hip Replacement Reduce the Pain and the Hospitalisation Time","status":"RECRUITING","sponsor":"Ente Ospedaliero Cantonale, Bellinzona","startDate":"2021-12-10","conditions":["Femoral Neck Fractures"],"enrollment":110,"completionDate":"2026-11-01"},{"nctId":"NCT04216524","phase":"PHASE2","title":"Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-05-29","conditions":["Blastic Plasmacytoid Dendritic Cell Neoplasm"],"enrollment":40,"completionDate":"2026-12-31"},{"nctId":"NCT04663347","phase":"PHASE1,PHASE2","title":"Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-11-03","conditions":["Diffuse Large B-Cell Lymphoma","Follicular Lymphoma"],"enrollment":543,"completionDate":"2027-09-30"},{"nctId":"NCT03937635","phase":"PHASE3","title":"Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2019-09-16","conditions":["Smoldering Plasma Cell Myeloma"],"enrollment":288,"completionDate":"2029-12-31"},{"nctId":"NCT04566328","phase":"PHASE3","title":"Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-02-24","conditions":["Plasma Cell Myeloma","RISS Stage I Plasma Cell Myeloma","RISS Stage II Plasma Cell Myeloma"],"enrollment":1450,"completionDate":"2027-12-31"},{"nctId":"NCT06664853","phase":"PHASE3","title":"Open-Label Extension of EryDex Study IEDAT-04-2022","status":"TERMINATED","sponsor":"Quince Therapeutics S.p.A.","startDate":"2024-12-11","conditions":["Ataxia Telangiectasia"],"enrollment":101,"completionDate":"2026-01-30"},{"nctId":"NCT03283917","phase":"PHASE1","title":"Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-02-07","conditions":["Newly Diagnosed Primary Amyloidosis","Recurrent Primary Amyloidosis","Refractory Primary Amyloidosis"],"enrollment":21,"completionDate":"2027-05-18"},{"nctId":"NCT04764942","phase":"PHASE1,PHASE2","title":"Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2021-05-06","conditions":["Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":39,"completionDate":"2027-12-17"},{"nctId":"NCT03007147","phase":"PHASE3","title":"Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2017-08-08","conditions":["Acute Lymphoblastic Leukemia","B Acute Lymphoblastic Leukemia","Mixed Phenotype Acute Leukemia","T Acute Lymphoblastic Leukemia"],"enrollment":475,"completionDate":"2027-09-30"},{"nctId":"NCT05991388","phase":"PHASE2,PHASE3","title":"A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2024-05-02","conditions":["B-cell Non Hodgkin Lymphoma"],"enrollment":210,"completionDate":"2033-05-01"},{"nctId":"NCT07082270","phase":"PHASE1","title":"Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-04-01","conditions":["Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":21,"completionDate":"2028-02-01"},{"nctId":"NCT02339740","phase":"PHASE3","title":"Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2015-07-21","conditions":["Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA"],"enrollment":158,"completionDate":"2029-06-30"},{"nctId":"NCT04754945","phase":"PHASE1","title":"Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2021-04-28","conditions":["AL Amyloidosis"],"enrollment":11,"completionDate":"2026-07-24"},{"nctId":"NCT03136146","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-08-09","conditions":["Recurrent Acute Lymphoblastic Leukemia","Recurrent Adult Lymphoblastic Lymphoma","Recurrent Burkitt Leukemia","Recurrent Burkitt Lymphoma","Recurrent Childhood Lymphoblastic Lymphoma","Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","Refractory Acute Lymphoblastic Leukemia","Refractory Burkitt Leukemia","Refractory Burkitt Lymphoma","Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","Refractory Lymphoblastic Lymphoma"],"enrollment":42,"completionDate":"2027-08-01"},{"nctId":"NCT03710772","phase":"PHASE2","title":"Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-05-01","conditions":["Mantle Cell Lymphoma"],"enrollment":51,"completionDate":"2027-03-22"},{"nctId":"NCT06132685","phase":"PHASE2","title":"Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-01-09","conditions":["Low Grade Glioma","Malignant Brain Glioma","Malignant Brain Neoplasm","Meningioma"],"enrollment":200,"completionDate":"2028-07-30"},{"nctId":"NCT07101445","phase":"PHASE4","title":"Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-09-24","conditions":["Multiple Myeloma"],"enrollment":94,"completionDate":"2027-12-31"},{"nctId":"NCT03031730","phase":"PHASE1","title":"Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-06-14","conditions":["Plasmacytoma","Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":35,"completionDate":"2024-07-24"},{"nctId":"NCT07208799","phase":"PHASE2","title":"Comparison of Submucosal Dexamethasone and Methylprednisolone in Postoperative Sequelae of Parasymphsis Fractures","status":"RECRUITING","sponsor":"Nishtar Medical University","startDate":"2026-01-03","conditions":["Mandible Fracture","Edema Face","Pain Management","Corticosteroid Injection"],"enrollment":72,"completionDate":"2026-12-01"},{"nctId":"NCT07395232","phase":"PHASE3","title":"An Efficacy and Safety Study of DFL24498 in the Treatment of AKC","status":"RECRUITING","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2025-12-01","conditions":["Atopic Keratoconjunctivitis"],"enrollment":138,"completionDate":"2027-05"},{"nctId":"NCT06230224","phase":"PHASE3","title":"A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-02-15","conditions":["B-Cell Non-Hodgkin Lymphoma (B-NHL)"],"enrollment":216,"completionDate":"2027-05-14"},{"nctId":"NCT04743661","phase":"PHASE2","title":"131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pediatric Brain Tumor Consortium","startDate":"2022-04-04","conditions":["Recurrent Medulloblastoma","Recurrent Ependymoma"],"enrollment":62,"completionDate":"2027-09-30"},{"nctId":"NCT07388069","phase":"PHASE1,PHASE2","title":"Study of TN-001 Topical Eyedrops for Keratoconus","status":"ENROLLING_BY_INVITATION","sponsor":"TheiaNova Ltd.","startDate":"2025-12-23","conditions":["Keratoconus"],"enrollment":20,"completionDate":"2027-07-01"},{"nctId":"NCT05497804","phase":"PHASE2","title":"Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2022-09-22","conditions":["ISS Stage III Plasma Cell Myeloma","Multiple Myeloma"],"enrollment":17,"completionDate":"2028-11-20"},{"nctId":"NCT05981209","phase":"PHASE1","title":"Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies","status":"RECRUITING","sponsor":"Abdullah Khan","startDate":"2023-12-21","conditions":["Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":27,"completionDate":"2026-12-31"},{"nctId":"NCT04681105","phase":"PHASE1","title":"Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2020-11-18","conditions":["Recurrent Acute Leukemia","Recurrent B Acute Lymphoblastic Leukemia","Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm","Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Recurrent Hairy Cell Leukemia","Recurrent Hematologic Malignancy","Recurrent Hodgkin Lymphoma","Recurrent T Acute Lymphoblastic Leukemia","Refractory Acute Leukemia","Refractory B Acute Lymphoblastic Leukemia","Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm","Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Refractory Hairy Cell Leukemia","Refractory Hematologic Malignancy","Refractory Hodgkin Lymphoma","Refractory T Acute Lymphoblastic Leukemia","Systemic Mastocytosis"],"enrollment":13,"completionDate":"2025-08-05"},{"nctId":"NCT06213649","phase":"PHASE3","title":"Parasitic Ulcer Treatment Trial","status":"RECRUITING","sponsor":"Jeremy Keenan, MD, MPH","startDate":"2024-07-01","conditions":["Acanthamoeba Keratitis"],"enrollment":232,"completionDate":"2028-07"},{"nctId":"NCT06616584","phase":"PHASE2,PHASE3","title":"Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2025-05-22","conditions":["Recurrent Lung Non-Small Cell Carcinoma","Stage IV Lung Cancer AJCC v8"],"enrollment":378,"completionDate":"2028-12-31"},{"nctId":"NCT07345819","phase":"NA","title":"Dexamethasone vs. Placebo in Children and Youth Hospitalized for Orbital Cellulitis","status":"NOT_YET_RECRUITING","sponsor":"The Hospital for Sick Children","startDate":"2026-04-01","conditions":["Orbital Cellulitis"],"enrollment":30,"completionDate":"2027-12-31"},{"nctId":"NCT07343128","phase":"PHASE2,PHASE3","title":"Ultrasound-Guided Stellate Ganglion Block in Fibromyalgia","status":"COMPLETED","sponsor":"Sanliurfa Education and Research Hospital","startDate":"2025-06-01","conditions":["Fibromyalgia"],"enrollment":68,"completionDate":"2025-12-25"},{"nctId":"NCT06193200","phase":"PHASE3","title":"Evaluate the Neurological Effects of EryDex on Subjects With A-T","status":"COMPLETED","sponsor":"Quince Therapeutics S.p.A.","startDate":"2024-06-24","conditions":["Ataxia Telangiectasia"],"enrollment":105,"completionDate":"2025-12-17"},{"nctId":"NCT06627751","phase":"PHASE2","title":"Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2025-05-01","conditions":["Extramedullary Disease in Multiple Myeloma","Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":28,"completionDate":"2030-05-01"},{"nctId":"NCT07077850","phase":"NA","title":"Effect of IV Dexamethasone on Post-op Urinary Retention After Spinal Anesthesia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Al-Quds University","startDate":"2025-08-20","conditions":["Post Operative Urinary Retention","Spinal Aneshtesia"],"enrollment":1084,"completionDate":"2026-08-20"},{"nctId":"NCT05793060","phase":"PHASE4","title":"Dexmedetomidine Versus Dexamethasone as Adjuvants to Bupivacaine for Intermediate Cervical Plexus Block","status":"RECRUITING","sponsor":"Damanhour Teaching Hospital","startDate":"2025-08-01","conditions":["Analgesia"],"enrollment":60,"completionDate":"2026-12-15"},{"nctId":"NCT03808610","phase":"PHASE1,PHASE2","title":"Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-04-03","conditions":["Recurrent B Acute Lymphoblastic Leukemia","Recurrent T Acute Lymphoblastic Leukemia","Refractory B Acute Lymphoblastic Leukemia","Refractory T Acute Lymphoblastic Leukemia"],"enrollment":50,"completionDate":"2026-12-31"},{"nctId":"NCT02106988","phase":"PHASE2","title":"Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-01-16","conditions":["Lymphoma"],"enrollment":40,"completionDate":"2034-01-31"},{"nctId":"NCT00501826","phase":"PHASE2","title":"Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-07-11","conditions":["T Acute Lymphoblastic Leukemia","T Lymphoblastic Lymphoma"],"enrollment":160,"completionDate":"2026-10-31"},{"nctId":"NCT07072585","phase":"PHASE2,PHASE3","title":"Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)","status":"NOT_YET_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2026-06-28","conditions":["Stage II T Lymphoblastic Leukemia/Lymphoma","Stage III T Lymphoblastic Leukemia/Lymphoma","Stage IV T Lymphoblastic Leukemia/Lymphoma","T Acute Lymphoblastic Leukemia","T Lymphoblastic Lymphoma"],"enrollment":1708,"completionDate":"2035-09-01"},{"nctId":"NCT03583255","phase":"PHASE2","title":"Physical Activity With or Without Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Locally Advanced, Metastatic, or Recurrent Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-06-29","conditions":["Advanced Malignant Solid Neoplasm","Hematopoietic and Lymphoid System Neoplasm","Locally Advanced Malignant Solid Neoplasm","Metastatic Malignant Solid Neoplasm","Recurrent Malignant Solid Neoplasm"],"enrollment":99,"completionDate":"2027-12-31"},{"nctId":"NCT07305987","phase":"PHASE3","title":"PRO-232 in Patients Subjected to Cataract Surgery","status":"RECRUITING","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2025-10-27","conditions":["Cataract Extraction"],"enrollment":134,"completionDate":"2026-07-30"},{"nctId":"NCT06042725","phase":"PHASE1","title":"MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-03-04","conditions":["Multiple Myeloma"],"enrollment":100,"completionDate":"2028-12-01"},{"nctId":"NCT06383572","phase":"PHASE1,PHASE2","title":"Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-06-26","conditions":["Lymphodepleting Chemotherapy","Myeloid Malignancies"],"enrollment":44,"completionDate":"2029-04-01"},{"nctId":"NCT04551131","phase":"PHASE1,PHASE2","title":"Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2021-07-13","conditions":["Hemophagocytic Lymphohistiocytosis"],"enrollment":10,"completionDate":"2026-08"},{"nctId":"NCT02553460","phase":"PHASE1,PHASE2","title":"Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2016-01-29","conditions":["Acute Lymphoblastic Leukemia"],"enrollment":50,"completionDate":"2031-10"},{"nctId":"NCT01424982","phase":"PHASE2","title":"Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-10-05","conditions":["Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Acute Lymphoblastic Leukemia","Adult Acute Lymphoblastic Leukemia in Complete Remission","B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Philadelphia Chromosome Positive","Untreated Adult Acute Lymphoblastic Leukemia"],"enrollment":88,"completionDate":"2027-10-31"},{"nctId":"NCT03117751","phase":"PHASE2,PHASE3","title":"Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-03-29","conditions":["Acute Lymphoblastic Leukemia","Acute Lymphoblastic Lymphoma"],"enrollment":790,"completionDate":"2028-09-30"},{"nctId":"NCT02101853","phase":"PHASE3","title":"Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-12-17","conditions":["Recurrent B Acute Lymphoblastic Leukemia"],"enrollment":669,"completionDate":"2026-09-16"},{"nctId":"NCT02112916","phase":"PHASE3","title":"Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-10-04","conditions":["Adult T Acute Lymphoblastic Leukemia","Ann Arbor Stage II Adult Lymphoblastic Lymphoma","Ann Arbor Stage II Childhood Lymphoblastic Lymphoma","Ann Arbor Stage III Adult Lymphoblastic Lymphoma","Ann Arbor Stage III Childhood Lymphoblastic Lymphoma","Ann Arbor Stage IV Adult Lymphoblastic Lymphoma","Ann Arbor Stage IV Childhood Lymphoblastic Lymphoma","Childhood T Acute Lymphoblastic Leukemia"],"enrollment":847,"completionDate":"2026-09-16"},{"nctId":"NCT02003222","phase":"PHASE3","title":"Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-05-19","conditions":["Acute Lymphoblastic Leukemia","B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative"],"enrollment":488,"completionDate":"2026-03-25"},{"nctId":"NCT00098475","phase":"PHASE3","title":"Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-11-03","conditions":["DS Stage I Multiple Myeloma","DS Stage II Multiple Myeloma","DS Stage III Multiple Myeloma"],"enrollment":452,"completionDate":"2026-10-23"},{"nctId":"NCT02883049","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2012-02-29","conditions":["B Acute Lymphoblastic Leukemia","B Acute Lymphoblastic Leukemia, BCR-ABL1-Like","Central Nervous System Leukemia","Testicular Leukemia"],"enrollment":5949,"completionDate":"2026-10-03"},{"nctId":"NCT07233577","phase":"NA","title":"The Effect of Dexamethasone in Full Pulpotomy on Postoperative Pain in Permanent Molars","status":"COMPLETED","sponsor":"Cukurova University","startDate":"2024-12-18","conditions":["Pulpitis - Irreversible"],"enrollment":72,"completionDate":"2025-06-16"},{"nctId":"NCT02427620","phase":"PHASE2","title":"Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-06-03","conditions":["Blastoid Variant Mantle Cell Lymphoma","Mantle Cell Lymphoma","Pleomorphic Variant Mantle Cell Lymphoma"],"enrollment":131,"completionDate":"2027-06-30"},{"nctId":"NCT05514990","phase":"PHASE1,PHASE2","title":"Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2022-10-07","conditions":["Recurrent Plasma Cell Myeloma","Refractory Plasma Cell Myeloma"],"enrollment":10,"completionDate":"2027-08-22"},{"nctId":"NCT07227584","phase":"PHASE2","title":"ALL Backbone in AYAs","status":"NOT_YET_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2026-04","conditions":["Acute Lymphoblastic Leukemia","Philadelphia Chromosome-Negative Lymphoblastic Leukemia","Acute Lymphoblastic Leukemia (ALL)","Leukemia"],"enrollment":67,"completionDate":"2035-07-31"},{"nctId":"NCT03367156","phase":"PHASE2","title":"Dexamethasone in Controlling Dyspnea in Patients With Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-12-04","conditions":["Dyspnea","Malignant Neoplasm"],"enrollment":135,"completionDate":"2025-12-31"},{"nctId":"NCT02877303","phase":"PHASE2","title":"Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-11-01","conditions":["B Acute Lymphoblastic Leukemia","B Lymphoblastic Lymphoma"],"enrollment":80,"completionDate":"2026-11-01"},{"nctId":"NCT03132454","phase":"PHASE1","title":"Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-07-25","conditions":["Recurrent Acute Lymphoblastic Leukemia","Recurrent Acute Myeloid Leukemia","Refractory Acute Lymphoblastic Leukemia","Refractory Acute Myeloid Leukemia"],"enrollment":32,"completionDate":"2027-12-31"},{"nctId":"NCT04329728","phase":"PHASE1,PHASE2","title":"The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies","status":"RECRUITING","sponsor":"AVM Biotechnology Inc","startDate":"2020-11-06","conditions":["Lymphoid Malignancies"],"enrollment":144,"completionDate":"2026-12-01"},{"nctId":"NCT05392946","phase":"PHASE1,PHASE2","title":"Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2022-08-11","conditions":["Plasma Cell Myeloma"],"enrollment":49,"completionDate":"2028-05-31"},{"nctId":"NCT03763162","phase":"PHASE2","title":"Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-01-17","conditions":["Recurrent Plasma Cell Myeloma","Refractory Plasma Cell Myeloma"],"enrollment":40,"completionDate":"2027-10-30"},{"nctId":"NCT03231150","phase":"NA","title":"Plantar Fasciitis Randomized Clinical Control Trial","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2017-03-28","conditions":["Plantar Fascitis"],"enrollment":62,"completionDate":"2026-10-31"},{"nctId":"NCT04366115","phase":"PHASE1","title":"Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS","status":"NOT_YET_RECRUITING","sponsor":"AVM Biotechnology Inc","startDate":"2026-12-01","conditions":["ARDS","Covid19","Influenza, Human"],"enrollment":16,"completionDate":"2032-03-01"},{"nctId":"NCT06785415","phase":"PHASE1,PHASE2","title":"Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-03-18","conditions":["Recurrent Multiple Myeloma"],"enrollment":37,"completionDate":"2031-04-01"},{"nctId":"NCT06905509","phase":"PHASE2","title":"Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Joseph Tuscano","startDate":"2025-07-31","conditions":["Recurrent Diffuse Large B-Cell Lymphoma","Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements","Recurrent High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements","Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified","Recurrent Nodal Marginal Zone Lymphoma","Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma","Refractory Diffuse Large B-Cell Lymphoma","Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements","Refractory High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements","Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified","Refractory Nodal Marginal Zone Lymphoma","Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma"],"enrollment":25,"completionDate":"2030-08-01"},{"nctId":"NCT03367572","phase":"PHASE3","title":"Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer","status":"COMPLETED","sponsor":"University of Rochester NCORP Research Base","startDate":"2018-04-19","conditions":["Breast Carcinoma"],"enrollment":1363,"completionDate":"2024-04-13"},{"nctId":"NCT04537026","phase":"PHASE1,PHASE2","title":"Sterile Amniotic Fluid Filtrate Epidural Injection.","status":"COMPLETED","sponsor":"University of Utah","startDate":"2021-06-16","conditions":["Lumbar Spinal Stenosis"],"enrollment":61,"completionDate":"2025-07-01"},{"nctId":"NCT04697940","phase":"PHASE1,PHASE2","title":"Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Han weidong","startDate":"2021-04-15","conditions":["Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma","Decitabine-primed Tandem CD19/CD20 CAR T Cells"],"enrollment":33,"completionDate":"2026-09-01"},{"nctId":"NCT05887765","phase":"PHASE4","title":"Effect of Systematic Dexamethasone on the Duration of Popliteal Nerve Block for Anesthesia After Pediatric Ankle Surgery","status":"COMPLETED","sponsor":"Poznan University of Medical Sciences","startDate":"2023-10-17","conditions":["Ankle Disease","Foot Deformities","Foot Diseases","Cerebral Palsy"],"enrollment":90,"completionDate":"2025-07-29"},{"nctId":"NCT04776395","phase":"PHASE2","title":"Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma","status":"RECRUITING","sponsor":"Emory University","startDate":"2021-11-02","conditions":["Smoldering Plasma Cell Myeloma"],"enrollment":68,"completionDate":"2029-09-01"},{"nctId":"NCT06022939","phase":"PHASE3","title":"Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2024-07-01","conditions":["AL Amyloidosis"],"enrollment":338,"completionDate":"2030-10-29"},{"nctId":"NCT04546399","phase":"PHASE2","title":"A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-12-17","conditions":["Down Syndrome","Recurrent B Acute Lymphoblastic Leukemia"],"enrollment":461,"completionDate":"2028-06-30"},{"nctId":"NCT01863550","phase":"PHASE3","title":"Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2013-12-06","conditions":["Plasma Cell Myeloma"],"enrollment":1087,"completionDate":"2034-02-05"},{"nctId":"NCT01415882","phase":"PHASE2","title":"Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2012-01-31","conditions":["Recurrent Plasma Cell Myeloma","Refractory Plasma Cell Myeloma"],"enrollment":165,"completionDate":"2025-04-30"},{"nctId":"NCT05208307","phase":"PHASE2","title":"Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma","status":"RECRUITING","sponsor":"Emory University","startDate":"2022-07-21","conditions":["Plasma Cell Myeloma"],"enrollment":34,"completionDate":"2027-10-21"},{"nctId":"NCT02819024","phase":"NA","title":"Dexamethasone Effects in Patients With Refractory Non-Small Cell Lung Cancer Using FLT Positron Emission Tomography","status":"COMPLETED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2016-06","conditions":["Recurrent Non-Small Cell Lung Carcinoma","Stage IIIA Non-Small Cell Lung Cancer","Stage IIIB Non-Small Cell Lung Cancer","Stage IV Non-Small Cell Lung Cancer"],"enrollment":6,"completionDate":"2019-10-17"},{"nctId":"NCT07134075","phase":"PHASE2","title":"Intracochlear Injection of Glucocorticoid","status":"NOT_YET_RECRUITING","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2025-08-25","conditions":["Sudden Sensorineural Hearing Loss (SSNHL)"],"enrollment":150,"completionDate":"2027-08-01"},{"nctId":"NCT04862585","phase":"PHASE2,PHASE3","title":"Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel","status":"COMPLETED","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2021-10-07","conditions":["Anatomic Stage 0 Breast Cancer AJCC v8","Anatomic Stage I Breast Cancer AJCC v8","Anatomic Stage IA Breast Cancer AJCC v8","Anatomic Stage IB Breast Cancer AJCC v8","Anatomic Stage II Breast Cancer AJCC v8","Anatomic Stage IIA Breast Cancer AJCC v8","Anatomic Stage IIB Breast Cancer AJCC v8","Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IIIA Breast Cancer AJCC v8","Anatomic Stage IIIB Breast Cancer AJCC v8","Anatomic Stage IIIC Breast Cancer AJCC v8","Anatomic Stage IV Breast Cancer AJCC v8","Breast Carcinoma","Prognostic Stage 0 Breast Cancer AJCC v8","Prognostic Stage I Breast Cancer AJCC v8","Prognostic Stage IA Breast Cancer AJCC v8","Prognostic Stage IB Breast Cancer AJCC v8","Prognostic Stage II Breast Cancer AJCC v8","Prognostic Stage IIA Breast Cancer AJCC v8","Prognostic Stage IIB Breast Cancer AJCC v8","Prognostic Stage III Breast Cancer AJCC v8","Prognostic Stage IIIA Breast Cancer AJCC v8","Prognostic Stage IIIB Breast Cancer AJCC v8","Prognostic Stage IIIC Breast Cancer AJCC v8","Prognostic Stage IV Breast Cancer AJCC v8"],"enrollment":130,"completionDate":"2024-06-21"},{"nctId":"NCT05288062","phase":"PHASE2","title":"Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2022-06-15","conditions":["Plasma Cell Myeloma","Recurrent Plasma Cell Myeloma","Refractory Plasma Cell Myeloma","Smoldering Plasma Cell Myeloma"],"enrollment":17,"completionDate":"2024-07-25"},{"nctId":"NCT03015792","phase":"PHASE1","title":"Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2017-03-10","conditions":["Recurrent Plasma Cell Myeloma","Refractory Plasma Cell Myeloma"],"enrollment":18,"completionDate":"2022-10-18"},{"nctId":"NCT07078786","phase":"PHASE4","title":"Effect of Pre-delivery Dexamethasone in Comparison With Betamethasone on Fetal Heart Trace","status":"RECRUITING","sponsor":"Rawalpindi Medical College","startDate":"2025-07-13","conditions":["Cardiotocography","Steroids"],"enrollment":110,"completionDate":"2025-10-15"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intramuscular","formulation":"Injection","formulations":[{"form":"INJECTION","route":"INTRA-ARTICULAR","productName":"Dexamethasone Sodium Phosphate"},{"form":"INJECTION","route":"INTRAMUSCULAR","productName":"DEXAMETHASONE SODIUM PHOSPHATE"},{"form":"INJECTION","route":"INTRAMUSCULAR","productName":"Dexamethasone Sodium Phosphate"},{"form":"INJECTION","route":"INTRAMUSCULAR","productName":"ReadySharp Dexamethasone"},{"form":"INJECTION","route":"INTRAMUSCULAR","productName":"Viadox"},{"form":"INJECTION","route":"INTRAVENOUS","productName":"DEXAMETHASONE Sodium Phosphate"},{"form":"INJECTION","route":"INTRAVENOUS","productName":"Dexamethasone Sodium Phosphate"},{"form":"INJECTION","route":"SOFT TISSUE","productName":"DEXAMETHASONE SODIUM PHOSPHATE"},{"form":"INJECTION, EMULSION","route":"INTRAMUSCULAR","productName":"Dexamethasone Sodium Phosphate"},{"form":"INJECTION, SOLUTION","route":"INTRA-ARTICULAR","productName":"Dexamethasone Sodium Phosphate"},{"form":"INJECTION, SOLUTION","route":"INTRALESIONAL","productName":"Dexamethasone Sodium Phosphate"},{"form":"INJECTION, SOLUTION","route":"INTRAMUSCULAR","productName":"DEXAMETHASONE SODIUM PHOSPHATE"},{"form":"INJECTION, SOLUTION","route":"INTRAMUSCULAR","productName":"Dexamethasone Sodium Phosphate"},{"form":"INJECTION, SOLUTION","route":"INTRAMUSCULAR","productName":"DMT SUIK"},{"form":"INJECTION, SOLUTION","route":"INTRAOCULAR","productName":"Dex-Moxi PF"}]},"crossReferences":{"NUI":"N0000148296","MMSL":"3245","NDDF":"002174","UNII":"2BP70L44PR","VUID":"4020650","CHEBI":"CHEBI:4462","VANDF":"4017922","INN_ID":"816","RXNORM":"227682","UMLSCUI":"C0770565","chemblId":"CHEMBL2021430","ChEMBL_ID":"CHEMBL1201302","KEGG_DRUG":"D00975","DRUGBANK_ID":"DB01234","PDB_CHEM_ID":" DEX","PUBCHEM_CID":"9400","SNOMEDCT_US":"372584003","SECONDARY_CAS_RN":"312-93-6","MESH_DESCRIPTOR_UI":"D003907","MESH_SUPPLEMENTAL_RECORD_UI":"C004180"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1959-","companyName":"Merck","relationship":"Original Developer"}],"publicationCount":375,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"originalDeveloper":"Merck","recentPublications":[{"date":"2025 Dec 18","pmid":"41411223","title":"Dexamethasone Dosing of Human Perilymph Compared for Common Delivery Protocols Using Inner Ear Simulations.","journal":"Audiology & neuro-otology"},{"date":"2026 Feb","pmid":"41340367","title":"Skin-to-Muscle Deep Tissue Stimulation System for Muscle Atrophy.","journal":"Advanced materials (Deerfield Beach, Fla.)"},{"date":"2025 Oct 7","pmid":"41090873","title":"Magnetic Cationic Liposomes-Based Delivery System Reduces Drug-Induced Cytotoxicity in an In Vitro Model of Hearing Loss.","journal":"Nanomaterials (Basel, Switzerland)"},{"date":"2025","pmid":"40699120","title":"Intravitreal aflibercept alone versus combination with dexamethasone phosphate for diabetic macular edema: A randomized phase-2 clinical trial.","journal":"Arquivos brasileiros de oftalmologia"},{"date":"2025 Jul 3","pmid":"40619775","title":"Adopting a consensus on the dose of antenatal steroids used by obstetric and neonatal services in Singapore in anticipation of imminent preterm birth.","journal":"Singapore medical journal"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Merck & Co.","companyId":"merck","modality":"Small Molecule","firstApprovalDate":"1959","aiSummary":"Dexamethasone Sodium Phosphate is a small molecule glucocorticoid receptor agonist used to treat various conditions, including Acute Respiratory Distress Syndrome, Multiple Myeloma, Non-small Cell Lung Cancer, Vomiting, and Nausea. It is a fluorinated glucocorticoid medication that works by activating the glucocorticoid receptor, and is used to treat conditions such as severe allergies, asthma, and chronic obstructive pulmonary disease (COPD).","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1959-09-02T00:00:00.000Z","mah":"MERCK","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1962-09-17T00:00:00.000Z","mah":"UCB INC","brand_name_local":"DEXACORT","application_number":"NDA013413"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1964-12-04T00:00:00.000Z","mah":"ASPEN GLOBAL INC","brand_name_local":"HEXADROL","application_number":"NDA014694"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1974-12-19T00:00:00.000Z","mah":"SOLA BARNES HIND","brand_name_local":"DEXAMETHASONE SODIUM PHOSPHATE","application_number":"ANDA084170"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1975-02-18T00:00:00.000Z","mah":"SOLA BARNES HIND","brand_name_local":"DEXAMETHASONE SODIUM PHOSPHATE","application_number":"ANDA084173"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1975-07-15T00:00:00.000Z","mah":"HIKMA","brand_name_local":"DEXAMETHASONE SODIUM PHOSPHATE","application_number":"ANDA084282"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1981-05-29T00:00:00.000Z","mah":"LYPHOMED","brand_name_local":"DEXAMETHASONE SODIUM PHOSPHATE","application_number":"ANDA087065"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1982-07-01T00:00:00.000Z","mah":"WATSON LABS","brand_name_local":"DEXAMETHASONE SODIUM PHOSPHATE","application_number":"ANDA087668"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1990-08-31T00:00:00.000Z","mah":"TEVA PARENTERAL","brand_name_local":"DEXAMETHASONE SODIUM PHOSPHATE","application_number":"ANDA081125"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1990-08-31T00:00:00.000Z","mah":"TEVA PARENTERAL","brand_name_local":"DEXAMETHASONE SODIUM PHOSPHATE","application_number":"ANDA081126"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1996-07-26T00:00:00.000Z","mah":"BAUSCH AND LOMB","brand_name_local":"DEXAMETHASONE SODIUM PHOSPHATE","application_number":"ANDA040069"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2005-04-22T00:00:00.000Z","mah":"FRESENIUS KABI USA","brand_name_local":"DEXAMETHASONE SODIUM PHOSPHATE","application_number":"ANDA040572"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2008-08-29T00:00:00.000Z","mah":"MYLAN LABS LTD","brand_name_local":"DEXAMETHASONE SODIUM PHOSPHATE","application_number":"ANDA040803"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2008-08-29T00:00:00.000Z","mah":"MYLAN LABS LTD","brand_name_local":"DEXAMETHASONE SODIUM PHOSPHATE","application_number":"ANDA040802"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2015-12-01T00:00:00.000Z","mah":"EUGIA PHARMA","brand_name_local":"DEXAMETHASONE SODIUM PHOSPHATE","application_number":"ANDA206781"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2018-04-19T00:00:00.000Z","mah":"SOMERSET THERAPS LLC","brand_name_local":"DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE","application_number":"ANDA207442"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2018-06-08T00:00:00.000Z","mah":"SOMERSET","brand_name_local":"DEXAMETHASONE SODIUM PHOSPHATE","application_number":"ANDA207521"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2018-08-22T00:00:00.000Z","mah":"AMNEAL","brand_name_local":"DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE","application_number":"ANDA208690"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2018-08-22T00:00:00.000Z","mah":"AMNEAL","brand_name_local":"DEXAMETHASONE SODIUM PHOSPHATE","application_number":"ANDA208689"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-05-10T00:00:00.000Z","mah":"SOMERSET THERAPS LLC","brand_name_local":"DEXAMETHASONE SODIUM PHOSPHATE","application_number":"ANDA211036"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2021-08-04T00:00:00.000Z","mah":"GLAND","brand_name_local":"DEXAMETHASONE SODIUM PHOSPHATE","application_number":"ANDA215654"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-07-07T00:00:00.000Z","mah":"GENEYORK PHARMS","brand_name_local":"DEXAMETHASONE SODIUM PHOSPHATE","application_number":"ANDA214890"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-08-01T00:00:00.000Z","mah":"HIKMA","brand_name_local":"DEXAMETHASONE SODIUM PHOSPHATE","application_number":"ANDA211451"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-03-27T00:00:00.000Z","mah":"MICRO LABS","brand_name_local":"DEXAMETHASONE SODIUM PHOSPHATE","application_number":"ANDA217797"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"QUAD PHARMS","brand_name_local":"DEXAMETHASONE SODIUM PHOSPHATE","application_number":"ANDA089281"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"QUAD PHARMS","brand_name_local":"DEXAMETHASONE SODIUM PHOSPHATE","application_number":"ANDA089282"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"WATSON LABS","brand_name_local":"DEXAMETHASONE SODIUM PHOSPHATE","application_number":"ANDA085606"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"WYETH AYERST","brand_name_local":"DEXAMETHASONE SODIUM PHOSPHATE","application_number":"ANDA085641"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"QUAD PHARMS","brand_name_local":"DEXAMETHASONE SODIUM PHOSPHATE","application_number":"ANDA089372"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"EPIC PHARMA LLC","brand_name_local":"DEXAMETHASONE SODIUM PHOSPHATE","application_number":"ANDA084493"},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Dexamethasone Taw","application_number":null},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"QUAD PHARMS","brand_name_local":"DEXAMETHASONE SODIUM PHOSPHATE","application_number":"ANDA089280"},{"country_code":"EU","regulator":"EMA","status":"withdrawn","approval_date":null,"mah":"Taw Pharma (Ireland) Ltd","brand_name_local":"Dexamethasone Taw","application_number":"EMEA/H/C/005740"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"INTL MEDICATION","brand_name_local":"DEXAMETHASONE SODIUM PHOSPHATE","application_number":"ANDA088522"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"PHARMAFAIR","brand_name_local":"NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE","application_number":"ANDA062539"}],"patentsNormalised":[{"patent_number":"8563027","territory":"US","patent_type":"Method of Use","expiry_date":"2030-02-12T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8409606","territory":"US","patent_type":"Formulation","expiry_date":"2030-05-14T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10799642","territory":"US","patent_type":"Formulation","expiry_date":"2032-05-11T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10028965","territory":"US","patent_type":"Method of Use","expiry_date":"2034-05-23T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10159683","territory":"US","patent_type":"Formulation","expiry_date":"2034-05-23T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10022502","territory":"US","patent_type":"Method of Use","expiry_date":"2034-06-22T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"12150896","territory":"US","patent_type":"Method of Use","expiry_date":"2036-10-07T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11458041","territory":"US","patent_type":"Method of Use","expiry_date":"2037-11-16T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11304961","territory":"US","patent_type":"Formulation","expiry_date":"2037-12-18T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10537585","territory":"US","patent_type":"Formulation","expiry_date":"2037-12-18T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11097061","territory":"US","patent_type":"Formulation","expiry_date":"2039-06-23T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"12144889","territory":"US","patent_type":"Method of Use","expiry_date":"2041-04-26T00:00:00.000Z","status":"active","paragraph_iv_filed":false}],"trialStats":{"total":12,"withResults":3},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T02:10:21.650280+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}